Author(s): Thomsen SF
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with profound negative impact on quality of life. Adalimumab (anti-TNF) is indicated for moderate-to-severe HS unresponsive to conventional therapy. Herein, studies of the change in Dermatology Life Quality Index (DLQI) among patients with HS treated with adalimumab are reviewed. The anticipated gain in DLQI is only modest in patients with HS treated with adalimumab, even in trials of high quality, and does not exceed the established minimal clinically important difference. Biologics targeting other inflammatory cytokines are warranted in the treatment of HS.
Dermatology Journal and/or Publisher
Journal Name: The Journal of dermatological treatment
Journal Abbreviation: J Dermatolog Treat
Journal Date Published:
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/29671663
Lasted Revision: 2018-04-19
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).
Tags: Adalimumab Biologicals HUMIRA Inflammatory